Wed, Jul 23, 2014, 2:53 AM EDT - U.S. Markets open in 6 hrs 37 mins

Recent

% | $
Click the to save as a favorite.

Regenerx Biopharmaceuticals Inc. Message Board

  • bocamp1 bocamp1 Apr 22, 2014 2:11 PM Flag

    Recent Deals

    AGN now gone. Bausch and Lomb gone.
    Seems like the eye area here could be huge.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Yeah, and both AGN and Bausch and Lomb went to one company, Valeant. Which means if they are successful in the end getting AGN.they would own a very significant amount of the total "eye" space therapies…which means a lot of other pharmas that have eye therapies are playing from way behind the eight ball… both AGN and B&L have very significant research going on…..combine the two and it woudl be formidable. I would think (hope??) that it might force companies now competing with VAleant (AGN and B&L)..to take a much harder look at their own R&D and therapies in the works.because if they want to compete…they need drugs…and to find new eye drugs - if they can't find them in-house.you better start looking for targets elsewhere. That's why this NICE news is so significant. It will put TB 4 on the "map" if the NHS says to NICE to go ahead and do the final work to approve TB 4 for use in dry eye in the UK. Considering the market cap of RGRX is a mere scrap of handful of millions…someone shoudl come knocking. An England approval is REVENUES.and other possible countries as well that have agreements with NICE ight piggyback approval quickly. Who knows, maybe Valeant will come knocking. They aren't scared to spend $$$ ($47 billion AGN)….and if TB 4 approved in England it will be a COMPETITOR to RESTASIS! Not good for Valeant. I think we hear within 4 weeks what NHS says. that is the key…NICE will take a while after that, tho'.

 
RGRX
0.1756+0.0006(+0.34%)Jul 22 1:48 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.